biotech stocks came under selling pressure along with the broader market as rate hike fears seized wall street the news flow however was scanty last week the food and drug administration expanded the emergency use authorization it accorded for the pfizer inc nyse pfebiontech se nasdaq bntx vaccine the expanded approval allows the use of a single booster dose in individuals 12 through 15 years of age a third primary series dose for certain immunocompromised children 5 through 11 years of age and the shortening of time between completion of primary vaccination and a booster dose to at least five months clinical readouts resulted in contrasting stock moves lixte biotechnology holdings inc nasdaq lixt ended the week up about 80 after its lead candidate lb100 was found to increase the responsiveness of diverse cancers to immunotherapy on the other hand aligos therapeutics inc nasdaq algs posted weekly declines of about 67 after it announced halting of the further development of its stops drug candidate alg010133 in phase 1 development to address chronic hepatitis b here are the key catalysts that could impact trading in biotech stocks in the unfolding week bridgewater new jerseybased hillstream biopharma inc nasdaq hils proposes offering 3 million shares in an initial public offering at an estimated price range of 5 and 6 the company has applied for listing its shares on the nasdaq under the ticker symbol hils hillstream is a preclinical biotechnology company developing therapeutic candidates targeting ferroptosis an emerging new anticancer mechanism resulting in ironmediated cell death for treatmentresistant cancers related link pfizers oral covid19 antiviral treatment paxlovid approved for use in uk given the fourthquarter earnings will kickstart in earnest in late january there could be a slew of preannouncements that could move stocks watch out for market moving news from the jpm healthcare conference the 3day healthcare conference hosted by jpmorgan chase  co nyse jpm gets underway on monday the annual affair is usually an inperson conference held in san francisco california this time around the conference has been moved to a virtual format after several companies dropped out due to omicron concerns the conference is the largest and most informative health care investment symposium in the industry connecting global industry leaders emerging fastgrowth companies innovative technology creators and investment community members several companies are expected to make preannouncements and announce clinical updates at the conference the focus is on presentations by companies about how they will navigate through another pandemic year amid the emergence of the omicron variant offtherecord negotiations deals and strategic discussions are also part of the conference